These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27794414)

  • 1. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
    Ohgami M; Kaburagi T; Kurosawa A; Homma M
    Lung Cancer; 2016 Nov; 101():9-10. PubMed ID: 27794414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant drug interaction: phenytoin toxicity due to erlotinib.
    Grenader T; Gipps M; Shavit L; Gabizon A
    Lung Cancer; 2007 Sep; 57(3):404-6. PubMed ID: 17383767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
    Svedberg A; Vikingsson S; Vikström A; Hornstra N; Kentson M; Branden E; Koyi H; Bergman B; Gréen H
    Br J Clin Pharmacol; 2019 Aug; 85(8):1704-1709. PubMed ID: 30945322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
    How J; Mann J; Laczniak AN; Baggstrom MQ
    Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
    BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
    BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
    Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
    Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
    Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC
    Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
    Bai H; Han B
    Am J Clin Oncol; 2013 Apr; 36(2):110-5. PubMed ID: 22391431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
    Weber B; Winterdahl M; Memon A; Sorensen BS; Keiding S; Sorensen L; Nexo E; Meldgaard P
    J Thorac Oncol; 2011 Jul; 6(7):1287-9. PubMed ID: 21847041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
    Becker A; van Wijk A; Smit EF; Postmus PE
    J Thorac Oncol; 2010 Sep; 5(9):1477-80. PubMed ID: 20736807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
    Kim MK; Yee J; Cho YS; Jang HW; Han JM; Gwak HS
    BMC Cancer; 2018 Oct; 18(1):988. PubMed ID: 30326853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
    [No Abstract]   [Full Text] [Related]  

  • 19. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
    Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced
    Ortega-Granados AL; Artal-Cortes Á; Aguiar-Bujanda D; Oramas J; Fírvida JL; DE Castro J; Fuentes JC; Gordo R; Galán R; Trigo J;
    Anticancer Res; 2019 Mar; 39(3):1317-1328. PubMed ID: 30842164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.